Israel Englander Millennium Management
Israel “Izzy” Englander is the founder of Millennium Management, one of the world’s largest multi-strategy hedge fund platforms. Millennium allocates capital across hundreds of independent teams rather than a single house view, with rigorous risk controls at the platform level. Englander’s model has been highly influential in the rise of pod-shop multi-manager structures across the industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$643M |
| 2 |
AT&T
T
|
+$311M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$306M |
| 4 |
Microsoft
MSFT
|
+$292M |
| 5 |
Ametek
AME
|
+$215M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$887M |
| 2 |
Apple
AAPL
|
+$694M |
| 3 |
PRAH
PRA Health Sciences, Inc.
PRAH
|
+$616M |
| 4 |
Amazon
AMZN
|
+$596M |
| 5 |
Linde
LIN
|
+$531M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 58.05% |
| 2 | Technology | 7.69% |
| 3 | Financials | 6.83% |
| 4 | Healthcare | 6.42% |
| 5 | Industrials | 4.98% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TCFC
3926
DELISTED
The Community Financial Corporation Common Stock
TCFC
| $1.93M | ﹤0.01% |
52,318
-28,832
| -36% | -$1.03M |
|
3927
SAB Biotherapeutics
SABS
$345M
| $1.93M | ﹤0.01% |
19,131
+15,465
| +422% | +$1.54M |
|
3928
CALL
Glaukos
GKOS
$10.6B
| $1.93M | ﹤0.01% |
40,000
+25,000
| +167% | +$1.39M |
|
|
HIIIU
3929
DELISTED
Hudson Executive Investment Corp. III Unit
HIIIU
| $1.93M | ﹤0.01% |
195,657
-689,134
| -78% | -$6.83M |
|
3930
Algonquin Power & Utilities
AQN
$4.36B
| $1.92M | ﹤0.01% |
131,071
-55,221
| -30% | -$852K |
|
|
HCCC
3931
DELISTED
Healthcare Capital Corp. Class A common stock
HCCC
| $1.92M | ﹤0.01% |
194,858
+179,858
| +1,199% | +$1.77M |
|
|
OCAX
3932
DELISTED
OCA Acquisition Corp. Class A Common Stock
OCAX
| $1.92M | ﹤0.01% |
193,827
-30,173
| -13% | -$297K |
|
3933
Autoliv
ALV
$8.94B
| $1.92M | ﹤0.01% |
22,374
-88,535
| -80% | -$8.17M |
|
3934
PUT
VanEck Junior Gold Miners ETF
GDXJ
$9.48B
| $1.92M | ﹤0.01% |
50,000
| – | – |
|
3935
Mitsubishi UFJ Financial
MUFG
$258B
| $1.92M | ﹤0.01% |
323,285
+304,985
| +1,667% | +$1.69M |
|
3936
AEON Biopharma
AEON
$15.7M
| $1.92M | ﹤0.01% |
2,732
+1,444
| +112% | +$1.01M |
|
3937
Madrigal Pharmaceuticals
MDGL
$12.3B
| $1.92M | ﹤0.01% |
24,019
-21,864
| -48% | -$1.89M |
|
3938
RPC Inc
RES
$1.42B
| $1.92M | ﹤0.01% |
394,005
-198,926
| -34% | -$832K |
|
|
CFIV
3939
DELISTED
CF Acquisition Corp. IV Class A common stock
CFIV
| $1.92M | ﹤0.01% |
196,854
+54,267
| +38% | +$527K |
|
3940
Adeia
ADEA
$2.84B
| $1.91M | ﹤0.01% |
383,984
+204,767
| +114% | +$1.1M |
|
|
SHACU
3941
DELISTED
SCP & CO Healthcare Acquisition Company Unit
SHACU
| $1.91M | ﹤0.01% |
192,000
-493,412
| -72% | -$4.94M |
|
3942
NetApp
NTAP
$36.7B
| $1.91M | ﹤0.01% |
21,285
-282,831
| -93% | -$23.9M |
|
3943
PUT
Stellantis
STLA
$20.4B
| $1.91M | ﹤0.01% |
100,000
| – | – |
|
3944
ACI Worldwide
ACIW
$5.43B
| $1.91M | ﹤0.01% |
62,128
+8,291
| +15% | +$275K |
|
|
AMAM
3945
DELISTED
Ambrx Biopharma Inc
AMAM
| $1.91M | ﹤0.01% |
141,431
-2,661
| -2% | -$47.9K |
|
3946
CALL
Boston Properties
BXP
$11.1B
| $1.91M | ﹤0.01% |
17,600
-32,400
| -65% | -$3.7M |
|
3947
AdvanSix
ASIX
$445M
| $1.91M | ﹤0.01% |
47,942
-77,910
| -62% | -$2.68M |
|
3948
CALL
eBay
EBAY
$47B
| $1.9M | ﹤0.01% |
27,300
-348,000
| -93% | -$24.9M |
|
3949
US Foods
USFD
$23.2B
| $1.9M | ﹤0.01% |
54,848
-210,953
| -79% | -$7.24M |
|
|
GTY
3950
Getty Realty Corp
GTY
$2.04B
| $1.9M | ﹤0.01% |
64,770
-29,305
| -31% | -$915K |
|
Similar funds
Israel Englander's Q3 2021 Portfolio in Review
As of Q3 2021, Israel Englander held 7,698 positions worth $167B, up 2.3% from $163B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Israel Englander's Q3 2021 filing shows 1,245 new, 2,719 increased, 2,446 reduced and 981 closed positions. Its largest new stake was Sight Sciences: 1,577,092 shares worth $35.8M. The largest sale was Alexion Pharmaceuticals, an estimated $887M.
By sector, the portfolio is most concentrated in Miscellaneous at 58% of assets, up from 55% a quarter earlier, followed by Technology and Financials.
- Israel Englander's largest Q3 2021 buy was Sight Sciences: 1,577,092 shares worth $35.8M.
- Israel Englander added most to State Street SPDR S&P 500 ETF Trust in Q3 2021, an estimated $643M increase.
- Israel Englander's biggest Q3 2021 reduction was Apple, cutting an estimated $694M.
- Israel Englander fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $887M.
- Israel Englander's ten largest holdings make up 18% of its $167B portfolio in Q3 2021.
- Israel Englander opened 1,245 new positions and closed 981 in Q3 2021.
- Israel Englander's portfolio value rose 2.3% quarter-over-quarter to $167B.
Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.